All In Biotech

Drug Trial Radar · NCT07241416

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Study of Rezvilutamide Combined With Androgen Deprivation Therapy (ADT) Versus Enzalutamide Combined With ADT for Treating Low-volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

206

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Mar 2027

Study completion Sep 2028

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

  • Rezvilutamide TabletsDrug

    Rezvilutamide tablets, oral administration.

  • Enzalutamide Soft CapsulesDrug

    Enzalutamide soft capsules, oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prostate Specific Antigen (PSA) undetectable rate based on central laboratory.Time frame: 6 months after randomization.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.